Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy
Three-month results from a randomized study
Stephan B. Felix, MD*,
Alexander Staudt, MD*,
Wolf V. Dörffel, MD*,
Verena Stangl, MD*,
Kurt Merkel, MD ,
Manfred Pohl, PhD ,
Wolf D. Döcke, MD||,
Stanislao Morgera, MD ,
Hans H. Neumayer, MD ,
Klaus D. Wernecke, PhD¶,
Gerd Wallukat, PhD#,
Karl Stangl, MD* and
Gert Baumann, MD*
* Medizinische Klinik, Kardiologie Medizinische Klinik, Nephrologie Charité, Humboldt-Universtät zu Berlin, Berlin-Buch, Germany
Institut für Pathologie und Dermatohistologie, Diagnostisches Zentrum Berlin, Berlin-Buch, Germany
Institut für Medizinische Biophysik, Berlin-Buch, Germany
|| Immunologie, Berlin-Buch, Germany und
¶ Biometrie, Charité, Humboldt-Universtät zu Berlin, Berlin-Buch, Germany
# Max Delbrück Zentrum für Molekulare Medizin, Berlin-Buch, Germany

View larger version (13K):
[in a new window]
|
Figure 1 Time schedule of immunoadsorption (IA) and cardiovascular monitoring; IA was performed in four courses until the third month.
|
|

View larger version (27K):
[in a new window]
|
Figure 2 Changes in hemodynamics in the immunoadsorption/immunoglobulin group (IA/IgG group, filled bars, n = 9) and in the control group (controls, open bars, n = 9). (A) Cardiac index. (B) Stroke volume index. (C) Systemic vascular resistance. (D) Changes in left ventricular ejection fraction, as assessed by echocardiography. *p < 0.05; **p < 0.01 significantly different from baseline; +p < 0.05; ++p < 0.01 significantly different from controls.
|
|

View larger version (14K):
[in a new window]
|
Figure 3 Changes in beta-receptor antibody level in the immunoadsorption/immunoglobulin group (IA/IgG group, filled bars, n = 9) and in the control group (controls, open bars, n = 9). *p < 0.05; **p < 0.01 significantly different from baseline; +p < 0.05; ++p < 0.01 significantly different from controls.
|
|
|